Oncternal Therapeutics (ONCT) Short Interest Ratio & Short Volume → Amazon's betting big on this unknown AI company (From Manward Press) (Ad) Free ONCT Stock Alerts $8.84 +0.22 (+2.55%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Oncternal Therapeutics Short Interest DataCurrent Short Volume13,000 sharesPrevious Short Volume13,800 sharesChange Vs. Previous Month-5.80%Dollar Volume Sold Short$108,032.60Short Interest Ratio / Days to Cover1.8Last Record DateApril 30, 2024Outstanding Shares2,960,000 sharesFloat Size2,670,000 sharesShort Percent of Float0.49%Today's Trading Volume6,750 sharesAverage Trading Volume10,883 sharesToday's Volume Vs. Average62% Short Selling Oncternal Therapeutics ? Sign up to receive the latest short interest report for Oncternal Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatONCT Short Interest Over TimeONCT Days to Cover Over TimeONCT Percentage of Float Shorted Over Time Ad Banyan Hill PublishingLook Who Fired the World’s Richest ManThis company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman.Get the full story here. Oncternal Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202413,000 shares $108,032.60 -5.8%0.5%1.8 $8.31 4/15/202413,800 shares $121,440.00 -17.4%0.5%1.5 $8.80 3/31/202416,700 shares $150,300.00 +11.3%0.6%1.3 $9.00 3/15/202415,000 shares $120,300.00 -6.3%0.6%1 $8.02 2/29/202416,000 shares $148,800.00 -28.3%0.6%0.9 $9.30 2/15/202422,300 shares $200,477.00 -10.8%0.8%1.3 $8.99 Get the Latest News and Ratings for ONCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202425,000 shares $244,250.00 +25.0%0.9%1.5 $9.77 1/15/202420,000 shares $171,800.00 +52.7%0.8%1.2 $8.59 12/31/202313,100 shares $140,484.40 -94.6%0.4%0.9 $10.72 12/15/2023241,400 shares $91,732.00 -22.1%N/A1 $0.38 11/30/2023310,000 shares $114,080.00 -28.6%N/A1.7 $0.37 11/15/2023433,900 shares $140,974.11 +5.5%N/A2.9 $0.32 10/31/2023411,200 shares $139,561.28 +46.7%N/A2.5 $0.34 10/15/2023280,300 shares $82,688.50 +2.1%N/A1.7 $0.30 9/30/2023274,500 shares $82,350.00 -8.0%N/A1.4 $0.30 9/15/2023298,300 shares $104,405.00 +0.6%N/A1.4 $0.35 8/31/2023296,500 shares $88,950.00 -7.6%N/A1.2 $0.30 8/15/2023320,900 shares $120,979.30 -6.4%N/A1.2 $0.38 7/31/2023342,700 shares $126,901.81 -23.6%N/A1.3 $0.37 7/15/2023448,600 shares $205,593.38 +32.8%N/A1.7 $0.46 6/30/2023337,700 shares $116,506.50 -4.0%N/A0.9 $0.35 6/15/2023351,600 shares $140,640.00 +27.4%N/A0.6 $0.40 5/31/2023276,100 shares $78,688.50 +7.4%N/A0.5 $0.29 5/15/2023257,000 shares $75,815.00 -46.6%N/A0.5 $0.30 4/30/2023480,900 shares $147,395.85 -1.9%N/A0.9 $0.31 4/15/2023490,300 shares $153,120.69 +29.0%N/A1 $0.31 3/31/2023380,000 shares $298,300.00 -8.0%N/A0.8 $0.79 3/15/2023412,900 shares $300,426.04 +1.8%N/A1.8 $0.73 2/28/2023405,600 shares $361,632.96 -2.1%N/A1.5 $0.89 2/15/2023414,200 shares $426,626.00 -5.6%N/A1.6 $1.03 1/31/2023438,600 shares $491,232.00 -34.3%N/A1.6 $1.12 1/15/2023667,600 shares $861,204.00 -29.7%N/A2.4 $1.29 12/30/2022950,000 shares $950,000.00 +0.2%N/A3.4 $1.00 12/15/2022947,800 shares $871,976.00 +61.3%N/A3.4 $0.92 11/30/2022587,700 shares $534,865.77 -18.2%N/A2.1 $0.91 11/15/2022718,800 shares $725,988.00 +28.0%N/A2.8 $1.01 10/31/2022561,400 shares $589,470.00 -15.6%N/A1.7 $1.05 10/15/2022665,300 shares $725,177.00 -52.1%N/A1.8 $1.09 9/30/20221,390,000 shares $1.24 million +70.0%N/A3.3 $0.89 9/15/2022817,800 shares $801,525.78 +38.2%1.7%1.6 $0.98This Wall Street stock prediction just went viral (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history.Watch just the first 5 minutes of his new prediction ONCT Short Interest - Frequently Asked Questions What is Oncternal Therapeutics' current short interest? Short interest is the volume of Oncternal Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 13,000 shares of ONCT short. 0.49% of Oncternal Therapeutics' shares are currently sold short. Learn More on Oncternal Therapeutics' current short interest. What is a good short interest ratio for Oncternal Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ONCT shares currently have a short interest ratio of 2.0. Learn More on Oncternal Therapeutics's short interest ratio. What is a good short interest percentage for Oncternal Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.49% of Oncternal Therapeutics' floating shares are currently sold short. Is Oncternal Therapeutics' short interest increasing or decreasing? Oncternal Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 13,000 shares, a decline of 5.8% from the previous total of 13,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Oncternal Therapeutics' float size? Oncternal Therapeutics currently has issued a total of 2,960,000 shares. Some of Oncternal Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Oncternal Therapeutics currently has a public float of 2,670,000 shares. How does Oncternal Therapeutics' short interest compare to its competitors? 0.49% of Oncternal Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Oncternal Therapeutics: Unity Biotechnology, Inc. (2.16%), Iterum Therapeutics plc (7.68%), Acasti Pharma Inc. (0.02%), Forte Biosciences, Inc. (0.08%), Lisata Therapeutics, Inc. (0.22%), Biora Therapeutics, Inc. (4.52%), JanOne Inc. (2.00%), RenovoRx, Inc. (0.19%), Enlivex Therapeutics Ltd. (1.42%), Aptorum Group Limited (0.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Oncternal Therapeutics stock? Short selling ONCT is an investing strategy that aims to generate trading profit from Oncternal Therapeutics as its price is falling. ONCT shares are trading up $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncternal Therapeutics? A short squeeze for Oncternal Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ONCT, which in turn drives the price of the stock up even further. How often is Oncternal Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ONCT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Unity Biotechnology Short Interest Iterum Therapeutics Short Interest Acasti Pharma Short Interest Forte Biosciences Short Interest Lisata Therapeutics Short Interest Biora Therapeutics Short Interest JanOne Short Interest RenovoRx Short Interest Enlivex Therapeutics Short Interest Aptorum Group Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ONCT) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News